On September 24, 2019 Apexigen, Inc. reported its participation at the following upcoming oncology-focused conferences to discuss the role of the CD40 pathway in next-generation cancer immunotherapy and Apexigen’s lead product candidate APX005M, a monoclonal antibody targeting CD40 (Press release, Apexigen, SEP 24, 2019, View Source [SID1234539759]). APX005M is currently in multiple ongoing clinical trials in different solid tumor types. Ovid Trifan, M.D., Ph.D., Apexigen’s Chief Medical Officer and Senior Vice President, Clinical Development, will present at the following conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Breaking through emergent immunotherapy and immune targets in cancer (preceding the 2019 European Society for Medical Oncology [ESMO] Congress)
Casa de Convalescència, Barcelona, Spain
September 26, 2019

12th International Symposium on Translational Research in Oncology
Herbert Park Hotel, Dublin, Ireland
October 18, 2019

Additionally, a poster presentation entitled "Intratumoral CD40 Agonist (APX005M) in Combination with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in CPI Treatment Naïve Metastatic Melanoma" will be given at the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) (CICON 2019) at Espace Grande Arche De La Defense in Paris, France on September 27, 2019.